l S- AMLODIPINE BESYLATE [LEVA AMLODIPINE BESILATE]
Manufacturing Products Intermediates
l 5-CHLOROTHIOPHENE-2-CARBOXYLIC ACID FOR RIVAROXABAN
l (S)-2-(OXIRAN-2-YLMETHYL ISOINDOLINE-1, 3-DIONE (OR) (S)-GLYCIDYLPHTHALIMIDE FOR RIVAROXABAN
l 4-(4-AMINOPHENYL) MORPHOLIN-3-ONE FORRIVAROXABAN
l 4 HYDROXY PYRIDINE 3 SULFONIC ACID FOR TORSEMIDE
l 4-(3-METHYL PHENYL) AMINO-3-PYRIDINE SULFONAMIDE FORTORSEMIDE
l AMLODIPINE BASE
l S-AMLODIPINE BASE [LEVA AMLODIPINE BASE]
l SULPHONAMIDE OF GLIMIPRIDE
l SULPHONAMIDE OF GLIBENCLAMIDE
l 1-(4-METHYLPHENYL)-4,4, 4-TRIFLUORO-BUTANE-1,3-DIONE OF CELECOXIB
l 4-SULFONAMIDO PHENYL HYDRAZINE HYDROCHLORIDE OFCELECOXIB
l 4-HYDRAZINOBENZOIC ACID-HCL (4-HBA) FOR DEFERASIROX
l 2-(2-HYDROXYPHENYL)-4H-BENZO[E] [1,3] OXAZIN-4-ONE FOR DEFERASIROX
l KETOSULFONE OF ETORICOXIB
l KETOSULFONE OF ETORICOXIB
l CDT-SALT OR HF SALT OF ETORICOXIB
Gandhinagar to host Asia Labex 2024
Our bureau, Mumbai
Asia Labex will take place at Helipad Exhibition Center, Gandhinagar, Gujarat, India on 3 4 5th July 2024. Asia Labex is international exhibition and seminar on laboratory technology, analysis, biotechnology, diagnostic instruments, chemical & consumables products. It has been organized by Fenza Exhibitions Pvt. Ltd. Visiting industries of ASIALABEX Pharmaceuticals, Chemicals, Food & Beverages, Petrochemicals, Automobile, Hospitals, Govt. Agencies, Nanoscience & NanoTechnology, CRO, Oil & Petroleum, Cement, Agricultural, Metallurgy, Medical Laboratories, Water Testing,
Research, Textile, Fertilizers, Cosmetics, Material Testing, Education, Environmental, Many more…
EXHIBITION PROFILE
ANALYTICAL INSTRUMENTS, LAB & SCIENTIFIC INSTRUMENTS, CHROMATOGRAPHY, SPECTROSCOPY & MICROSCOPY, BIOTECHNOLOGY & LIFE SCIENCES, LAB FINE CHEMICALS & REAGENT, LAB CONSUMABLES, LAB GLASSWARE & PLASTIC WARE, LABORATORY BALANCES, MOLECULAR DIAGNOSTIC, CLINICAL DIAGNOSTIC, DIAGNOSTIC REAGENTS & EQUIPMENT, LABORATORY ANALYZERS, DIGITAL MEASURING INSTRUMENTS, SEROLOGY & RAPID TEST KITS, LABORATORY AUTOMATION & SOFTWARE, ENVIRONMENTAL LAB INSTRUMENTS, NANOTECHNOLOGY, DEHUMIDIFIERS, LABORATORY FURNITURE, MATERIAL TESTING INSTRUMENTS, WATER TREATMENT & FILTRATION, PROCESS INSTRUMENTS, EDUCATIONAL LAB PRODUCTS FOR ALL TURNKEY PROJECTS.
VISITOR PROFILE
CEO / MD, R&D OFFICERS & EXECUTIVES, PROFESSORS & LECTURERS, CHEMISTS & BIO CHEMISTS, LAB DIRECTORS, PURCHASE MANAGERS, DOCTORS, MICROBIOLOGISTS & PATHOLOGISTS, SCIENTISTS, LAB MANAGERS & TECHNICIANS, RESEARCH SCHOLARS, Q C / Q A MANAGERS, TRADE DEALERS, SCIENTIFIC OFFICERS, MANY MORE…
In today’s fastpaced world, staying ahead of the curve is crucial. Our panel discussion offers a unique opportunity for delegates to delve deep into the most pressing issues and emerging opportunities within the [industry/topic]. Whether you’re a seasoned professional, an aspiring entrepreneur, or a curious enthusiast,
ADVERTISING INDEX
INDIA'S ROAD TO INDEPENDENCE IN MANUFACTURING ACTIVE PHARMACEUTICAL INGREDIENTS (APIS)
Madhavi
B L R, Soundara Kalidass M,
Preeti Karwa
Introduction
TheIndian Pharma industry ranks 3rd in the world in terms of production volume (10%of global production), 14th in terms of value (1.5%), 4th for producing generics and 17thin terms of the value of its exported bulk actives and dosage forms. Based on a recent Ernst & Young Global Limited Federation of Indian Chambers of Commerce & Industry ( EY FICCI ) analysis, the pharmaceutical industry in India is expected to grow to be worth US$130 billion by 2030. Generic drugs, over the counter drugs, bulk drugs, vaccines, contract research and production, biosimilars, and biologics are important segments of the Indian pharmaceutical industry. More than 200 other countries import Indian pharmaceutical products, including heavily regulated markets in the US, Western Europe, Japan, and Australia. India has made significant strides in infrastructure, technology, and product diversity; its 500 API manufacturers account for 8% of the world market for APIs. India has over 262 pharmaceutical facilities approved by the US Food and Drug Administration (USFDA)—including API facilities, the greatest number of pharmaceutical facilities approved by the USFDA outside of the US.— and approximately 1400 plants complying with the Good Manufacturing Practices (GMP) of the World Health Organization. Furthermore, India exhibits cutting edge technological skills with 253 factories that have been certified by the European Directorate of Quality Medicines ( EDQM ) and by the regulatory authorities of other countries. API requirement– meeting the needs It is evident from the scenario of the Indian Pharm industry presented above regarding its global presence. That reflects the quantum of raw material necessary to fulfil global needs. s pharmaceutical exports were valued at USD 23.5 billion in 2021–2022, while imports totalled USD 8.06 billion, with a trade surplus of about 15.44 billion USD.In 202223, India imported $3.18 billion worth of APIs and intermediates from China.China was India's main
supplier of pharmaceutical API, accounting for 68.04% of the imports during the 2019–20 financial year. The USA ( 3.54% ) , Italy ( 3.02% ) , Singapore (2.88%), Spain (2.17%), Germany (1.85%), France (1.56%), Japan (1.53%), Denmark (1.26%), and Hong Kong ( 1.25% ) were among the other major providers. During the Covid pandemic, the restrictions on imports has terribly affected the output of the pharma industry. Reliance not just on China but other countries too for raw materials could prove to be challenging any time and adversely impact the Drug security and economy of India.
This reliance on imports is a result of India prioritizing formulations over bulk drugs due to concerns about profitability and strict environmental laws governing the manufacturing of bulk drugs.The interplay of drug price control order ( DPCO )National List of Essential medicines ( NLE, Geo political scenario, technological advancements, skilled human resource was not congenial for the indigenous manufacture of the APIs. Presently 384 medicines are listed in NLEM 2022. Though the objective of National Pharmaceutical Pricing Authority (NPPA) is at ensuring availability and accessibility of medicines at affordable pricesby regulatingtheir prices, from the perspective of a manufacturer the returns are discouraging. Be it China or any other country to import raw materials for the pharma industry, the ideal road ahead would be to encourage and facilitate domestic manufacture.
Meaures for selfsustenance Department of Pharmaceuticals introduced the Umbrella Scheme
for the Development of the Pharmaceutical Industry with the goal of reducing dependency on bulk imports of drugs and achieving self reliance (Atmanirbhar Bharat). The scheme consists of a number of subschemes designed to deal with these issues.
1. Assistance to Bulk Drug Industry for Common Facilitation Centres
2. Assistance to Medical Device Industry for Common Facilitation Centres
3. Assistance to Pharmaceutical Industry (CDPPS)
4. Pharmaceutical Promotion and Development Scheme (PPDS)
Assistance to bulk drug industry for Common Facilitation Centres
The Development of Common Facility Center for Bulk Drug (DCFCBD) was a Central Sector Scheme. This scheme was sanctioned Rs. 200 crore for 20182020. Onetime grant in aid given to a State Implementing Agency (SIA) that was formed especially to build the common facilities and infrastructure. The grant's principal objective was to provide financial assistance for the development of common facilities in upcoming bulk drug parks financed by governments and state corporations.
Assistance to Pharmaceutical Industry Cluster Development Programme for Pharma Sector (CDPPS)
The CDPPS was a program similar to a Central Sector Scheme. For the years 20182020, a budget of Rs. 20 crores was recommended. One
time grantsinaid were to be given to Special Purpose Vehicles (SPVs) established specifically for this initiative. The Public Private Partnership ( PPP ) structure is intended to facilitate the implementation of the Scheme.
Pharmaceutical Promotion and Development Scheme (PPDS)
The Pharmaceutical Promotion Development Scheme (PPDS) was initiated for expansion and exports in the pharmaceutical sector by providing funding for gatherings like conferences, seminars, and exhibitions. This would also facilitate delegations to visit and depart from India in order to promote exports and investments, carry out research and consultancy to address important issues and promote the expansion of the pharmaceutical industry.
This scheme's objective was to give interest subventions for eligible small and medium sized pharmaceutical companies with the capacity to manufacture pharmaceutical formulations and bulk drugs in accordance with Good Manufacturing Practices (GMP). A loan from a financial company is necessary for qualified units to modernize their production infrastructures and follow WHOGMP guidelines. The goal is to make it easier for Small and Medium Pharma Enterprises ( SMEs ) with a track record of profitability to move from Schedule M to WHO/GMP standards so they may compete globally and earn foreign exchange. This strategy proposed for allowance of more than 250 Pharma SMEs the access to the benefit of interest subvention
The following programs to promote the production of APIs have been approved by the Govt. of India.
1) As per the Press information bureau, March 2020, The Bulk Drug Park Promotion Scheme aimed to invest Rs. 3,000 crores for five years ahead to finance Common Infrastructure Facilities in three Bulk Drug Parks 2020–2021 to 2024–2025
2 ) The Production Linked Incentive ( PLI ) Scheme was launched to encourage domestic
(Continued on page ......5)
(Continued from page ......4)
production of vital Key Starting Materials ( KSMs ) , drug intermediates (DIs), and APIswith financial benefits of Rs. 6,940 crores for2020–2021 to 2029–2030 term.
Bulk Drug Parks
The Indian government took the decision to work with the states to create three large bulk drug parks throughout the nation. The government would provide funds to each bulk drug park, up to a total of Rs. 1000 crore. Electricity and steam units, distillation facilities, solvent recovery plants, and common effluent treatment plants are among the common facilities that these parks will feature. Government funding would cover 70% of the project cost for shared infrastructure in bulk drug parks that have been approved. For the Northeastern States and Hilly States ( which include Himachal Pradesh, Uttarakhand, Jammu & Kashmir, and Ladakh) 90% of the project cost would borne.
Production Linked Incentive (PLI) for manufacturing KSMs, DIs, and APIs
For a period of six years, manufacturers who produce any of the 53 approved bulk medications that meet the eligibility requirements will be eligible for financial incentives based on their increased sales over the 2019–20 base year. Amongst these drugs, 27 are chemically manufactured and 26 are based on fermentation. Incentives for fermentationbased bulk pharmaceuticals will be as follows: 15% for FY 2027–28, 5% for FY 2028–29, and 20% from FY 2023–24 to FY 2026–27. Incentives for chemically synthesized bulk drugs will be 10% during FY 2022–2023 and FY 2027–2028.
Target Segments
1 ) The fermentation based production segment consists of four KSMs or DIs with an estimated value of Rs. 400 crores. Penicillin G, 7ACA, Erythromycin Thiocynate and Clavulanic Acid are these compounds.
2) Within the fermentationbased category there are 10 niche KSMs, drug intermediates, and APIs belonging to that are estimated to be worth Rs. 50 crores. Neomycin, Gentamycin, Tetracycline, Vitamin B1, Rifampicin, Betamethasone, Dexamethasone, Prednisolone, and Clindamycin Base make up this category.
3) The Key Chemical Synthesisbased segment consists of four KSMs/Drug Intermediates with a combined value of Rs. 50 crores,. These compounds are 2Methyl5Nitro Imidazole ( 2 MNI ) , 1,1 Cyclohexane Diacetic Acid (CDA),
Government funding would cover 70% of the project cost for shared infrastructure in bulk drug parks that have been approved. For the Northeastern States and Hilly States (which include Himachal Pradesh, Uttarakhand, Jammu & Kashmir, and Ladakh) 90% of the project cost would borne.
Dicyandiamide
(DCDA), and Para Amino Phenol.
4) The remaining part consists of twentythree Chemical Synthesisbased KSMs, Drug Intermediates, and APIs totaling Rs. 20 crores. These consist of Aspirin, Diclofenac Sodium, Ritonavir, Lopinavir, Acyclovir, Carbamazepine, Oxcarbazepine, Vitamin B6, Artesunate, Telmisartan, Olmesartan, Valsartan, Losartan, Sulfadiazine, Ciprofloxacin, Ofloxacin, Norfloxacin, Carbidopa, Ritonavir, Carbidopa, Ritonavir, Lopinavir, Acyclovir, Carbamazepine, Oxcarbazepine, Vitamin B6 and Levofloxacin.
Production Linked Incentive for Pharmaceuticals
The pharmaceutical products were classified into three classes in the scheme:
1) Category 1: This comprises complex generic drugs, patentprotected drugs, genetherapy or cellbased drugs, orphan drugs, complex excipients, phytopharmaceuticals, and other approved drugs
2) Category 2: includes active pharmaceutical ingredients, key starting materials, drug intermediates etc.
3) Category 3: includes autoimmune drugs, anticancer drugs, antidiabetic drugs, anti infective drugs, cardiovascular drugs, psychotropic drugs, antiretroviral drugs, Invitro devices etc. These products are expected to give an impetus to innovation, R&D and product diversification Outcome of the Govt of India initiatives until 2023
PLI schemefor KSM/API/DI: Applications received 249; Approved applications 48, Commissioned approvals – 27, Invested amount Rs.3,063 crore ; Employment generated 2,777 persons; total sales made from the commissioned projectsRs.817.33 crore including Rs.252.62 crore exports; incentive amount released – Rs 4.34 Crore. PLI scheme of Pharmaceuticals –Shortlisted applications 55 applicants;: InvestmentRs.25,813 crore employment generated 56,171;. The sales made Rs.1,16,121 crore which
Accessed on 11th May 2024.
4. T C James. Bulk Drug Industry in India – Challenges and prospects’, Discussion paper. December 2020. Research and information system for developing countries. https://www.ris.org.in/sites/defau lt/files/Publication/Discussion%20 Paper%20259%20T%20C%20Jame s.pdfAccessed on 11th May 2024
includes exports of Rs.75,141 crore. The scheme envisages manufacturing of specialized category of pharmaceuticals/ IVD device. PTUAS 2 projects have been given final approval for capital subsidy on loan.
Conclusion
In summary, India's pharmaceutical sector has proven very resilient and has grown significantly, establishing itself as a global leader in manufacture and exports. Although remarkable advancements, numerous challenges still exist, most notably the need to import necessary raw materials. Nonetheless, the government has shown its commitment to national growth and selfreliance through proactive measures including schemes to support domestic production and foster innovation.
The Production Linked Incentive Scheme and the Bulk Drug Park Promotion Scheme are two examples that demonstrate India's commitment to strengthening its pharmaceutical industry for a stable and sustainable future. India is prepared to take advantage of the opportunities presented by the changing healthcare landscape through strategic improvements to its infrastructure, technology, and regulatory compliance. The proposed program initiatives to maintain the nation's current rate of growth while also making pharmaceutical innovation and accessibility far more accessible worldwide.
References:
1. ‘Pharma industry promotion’ https://www.pharmaceuticals.gov. in/pharmaindustrypromotionaccessed on 11th May 2024
2. ‘Department on Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India, Annual Report 202223 ‘ https://www.pharmaceuticals.gov. in/sites/default/files/Annual%20R eport%20202223%20Final3.pdfAccessed on 11th May 2024
3. India Brand Equity Foundation, Ministry of Commerce and Industry. ‘Indian Pharmaceutical Industry’ https://www.ibef.org/ industry/pharmaceuticalindia.
5. MoCF/Inauguration of PLI Projects.’ Press information Bureau. March2024. https://pib.gov.in/PressReleaseIfra mePage.aspx?PRID=2010924Acces sed on 11th May 2024
6. GUIDELINES FOR IMPLEMENTATION OF THE FIVE SUBSCHEMES UNDER THE SCHEME FOR DEVELOPMENT OF PHARMACEUTICALS INDUSTRY. https://pharmaceuticals.gov.in/sit es/default/files/SCHEME%20GUID ELINES.pdfAccessed on 11th May 2024
7. Invest India. ‘Production Linked Incentive (PLI) Schemes in India ‘ https://www.investindia.gov.in/pr oductionlinkedincentivesschemesindiaAccessed on 11th May 2024
8. Cabinet approves Promotion of domestic manufacturing of critical Key Starting Materials/Drug Intermediates and Active Pharmaceutical Ingredients in the country https://pib.gov.in/PressReleasePa ge.aspx?PRID=1607483Accessed on 11th May 2024
9.https://www.pharmaceuticals.g ov.in/sites/default/files/Gazettee %20notification%20of%20bulk%20 drug%20schemes_0_0.pdfAccesse d on 11th May 2024
10.https://www.pharmaceuticals.g ov.in/sites/default/files/Gazette% 20Notification%20of%20PLI%20sc heme%20for%20Pharmaceuticals_ 0_0.pdfAccessed on 11th May 2024
11.
https://www.thefinancialworld.co m/indianpharmaceuticalindustrysdependenceonchinaforapisksmsintermediatesahistoricalperspective/#:~:text=For%202022 %2D23%2C%20India%20imported, increase%20of%201.74%20per%2 0cent.Accessed on 11th May 2024 12. (https://www.globaltimes.cn/ page/202311/1302577.shtml)Acce ssed on 11th May 2024.
(Madhavi is from Department of Pharmaceutical Regulatory Affairs, Acharya & BM Reddy College of Pharmacy, whereas Soundara and Preeti are from Department of Pharmaceutics, AlAmeen College of Pharmacy)
INDIA'S ROAD TO INDEPENDENCE IN MANUFACTURING API
Sumel Ashique
ActivePharmaceutical Ingredient ( API ) manufacturing is an important segment of the Indian pharma industry. India ranks third in terms of volume of medicines produced, and is a major global supplier of generic medicines. However, India depends heavily on the import of several raw materials used to produce some of these medicines. India is merely following a path previously taken by many countries by outsourcing this low margin business of commodified APIs to countries like China, Singapore and Hong Kong, while Indian manufacturers focus more on highvalue APIs and on formulations (World Health Organization 2017b) India has today emerged as the “Pharmacy of the Global South”, with its pharmaceutical industry ranking third largest in the world in terms of medicines produced by volume. India accounts for 20% of global generic medicine exports by volume and supplies over 50% of global demand for vaccines (Indian Pharmaceutical Alliance 2019 ) Despite all of these achievements, the Indian pharmaceutical industry has, over the years, become significantly dependent on import of the basic raw materials that are used to produce the Finished Dosage Formulations.
The Government of India sees the high level of dependence on imports of APIs and intermediates from any single country as a threat to national health security and to the future of the Indian Pharma industry. Various committees/Task Forces have been appointed by Government of India, such as the Ministry of Health & Family Welfare’s Task Force on Formulating a Long Term Policy & Strategy for Strengthening of Drugs Sector in the Country and the Ministry of Commerce & Industry’s Task Force on Proposed Policy for Promotion of Pharma Innovation and Exports. The Boston Consultancy Group, Confederation of Indian Industry and Drug Manufacturers’ Association have made suggestions to strengthen the pharmaceutical sector with a focus on reducing the dependence for APIs, overall self reliance in the sector and promotion of exports. These developments were summarized by the Inter Ministerial Committee on APIs (Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. The Indian pharmaceutical industry
has been on an upward trajectory over the past few decades, contributing around 1.72 per cent of the GDP of the nation. The Indian pharma industry is anticipated to reach $ 65 bn by 2024 and $ 130 bn by 2030. This growth is driven by the increasing demand for affordable and high quality medicines, both domestically and internationally. Currently, India is the 3rd largest producer by volume and 14th largest by value worldwide. Indian pharma exports witnessed a growth of 103 per cent since 201314 – from INR 90, 415 Crores in 2013 14 to INR 1,83,422Crores in 202122. About 20% of the global exports in generic drugs are met by India, thereby making India “Pharmacy of the World”.
India’s API Industry
Active Pharmaceutical Ingredient (or API) is a crucial segment of the pharma industry, contributing to around 35 per cent of the market. API is the biologically active component of a drug that causes an intended medical effect. According to World Health Organization, API is any substance or combination of substances used in a finished pharmaceutical product ( or FPP ) intended to furnish pharmacological activity or to otherwise have direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to have an immediate impact in restoring, correcting, or modifying physiological functions in human beings.
India is the 3rd largest producer of API accounting for an 8 per cent share of the Global API Industry. 500+ different APIs are manufactured in India, and it contributes 57 per cent of APIs to prequalified list of the WHO. The Indian API market is anticipated to increase at a CAGR of 13.7 per cent during the first four years – about 8 per cent higher than the generic API industry. The Indian API space has become lucrative for several investors and venture capitalists.
India’s robust domestic market, advanced chemical industry, skilled workforce, stringent quality and manufacturing standards, and low costs (about 40 per cent less than that in the West) for setting up and operating a modern plant give an added advantage.
Government of India’s Schemes and Initiatives
To capitalize on its API potential, India is building a holistic and conducive ecosystem. In 2020, the government approved INR 6,940 crore for a production linked incentive ( PLI ) scheme for the promotion of domestic manufacturing of Key Starting Materials ( KSMs ) /Drug Intermediaries ( DIs ) , and APIs. Manufacturing of 35 active pharmaceutical ingredients –representing about 67 per cent of APIs for which India has 90 per cent import dependence – has already started in India under the PLI scheme. The Department of Pharmaceuticals has also given "inprinciple" approval to proposals from the states of Himachal Pradesh, Gujarat, and Andhra Pradesh under the "Promotion of Bulk Drug Parks" scheme. This is a crucial initiative to support bulk drug manufacturing in India.
The scheme, with a budget of INR 3000 crores, provides financial aid to these three states for the creation of bulk drug parks with the objective of reducing the cost of manufacturing bulk drugs by establishing world class common infrastructure facilities and increasing the competitiveness of the domestic bulk drug industry.
The Government of Assam has also proposed a Pharmaceutical Park in Chaygaon, Kamrup Rural on a land area of 100 acres with an estimated project cost of INR 153.64 crores. Furthermore, to promote innovation within the industry, various measures have been proposed such as raising the limit for foreign direct investment (up to 100 per cent, FDI has been allowed through automatic route for
Greenfield pharmaceuticals projects) and implementing a new strategy for protecting intellectual property rights.
India Active Pharmaceutical Ingredient (API) Market Forecast 20242028
The India active pharmaceutical ingredient market size is estimated to grow by USD 7.56 billion, at a CAGR of 6.49% between 2023 and 2028. The market research and growth report also includes an indepth analysis of drivers, trends, and challenges. Our market growth and forecasting report examines historical data from 2018 2022, besides analyzing the current market scenario.The market in India is gaining momentum due to rising healthcare spending in urban areas and a growing elderly population. Additionally, the surge in DMF filings, particularly type II DMFs, with the US FDA is contributing to this traction. Type II DMFs, which provide detailed information on drug substances and intermediates, are commonly filed, indicating increased outsourcing by pharmaceutical manufacturers. This trend underscores the reliance on Indian API manufacturers for generic and patented drug production, driving market growth.
India API Market Segmentation By Manufacturing Type Analysis
The market share by the captive APIs segment will be significant during the forecast period. The increased adoption of healthcare services has benefited the active pharmaceutical ingredient ( API ) market in India significantly. There is a huge focus on increasing the accessibility to affordable healthcare services, and this has led to increased demand for access to lowcost medicines, in turn inducing the demand for lowcost APIs for manufacturing finished drugs. Furthermore, the development of biopharmaceutical products incurs a huge investment of time and money, and even a small variation in the APIs can result in the spoilage of the entire batch of medicine, leading to significant financial loss to the innovator company. The captive APIs segment was valued at USD 9.81 billion in 2018. Furthermore, the increasing emphasis of healthcare regulatory authorities on quality control of APIs and their production facilities is a growing concern for manufacturers, resulting in increased dependency on inhouse capabilities for the manufacturing
(Continued on page ......8)
BY 2047, PHARMA INDUSTRY IS EXPECTED TO REACH AN IMPRESSIVE US$ 450 BILLION
Our bureau, Mumbai
The10th edition of PharmaLytica, organised by Informa Markets in India, commenced on 30th May at HITEX, Hyderabad, focusing on redefining the pharmaceutical industry in the postCOVID era. PharmaLytica 2024 offers a unique platform for stakeholders to engage in discussions covering the full spectrum of pharma machinery and packaging, lab analytical and cleanroom solutions, and pharmaceutical ingredients. As the Indian pharmaceutical industry is projected to grow from USD 65 billion in 2024 to US$ 130 billion by 2030, with CAGR of over 10%, the expo highlights its potential trajectory. By 2047, the industry is expected to reach an impressive US$ 450 billion, underscoring India's significant role in the global pharmaceutical landscape. PharmaLytica 2024 witnessed one of the largest gatherings of industry experts, technical heads, quality control and clinical researchers, purchase and packaging professionals, policy advisors, and other key stakeholders. The special inauguration ceremony was marked by the presence of key dignitaries such as Shri Ravi Uday Bhaskar, Director General, Pharmexcil; Shri AVPS Chakravarthi, Ambassador –World Packaging Organisation & Board Member, Pharmexcil; Mr. Orhan Yalman Okan,The Consul General, Consulate General of Turkey, Mr. Yogesh Mudras, Managing Director of Informa Markets in India and Mr. Rahul Deshpande, Senior Group Director, Informa Markets in India.
Highlighting the significant growth of Pharmaceutical Industry, Shri Ravi Uday Bhaskar, Director General of Pharmaceuticals Export Promotion Council of India ( Pharmexcil ) , said “During the pandemic and postpandemic period, the Indian pharmaceutical industry made significant contributions. We exported USD 27.8 billion worth of drugs in the financial year 2024, achieving a 9.6% growth rate despite numerous global challenges. We are expecting to reach more than USD 31 billion in the next financial year. 50% of our exports are going to highly regulated markets. In North America and Europe, it's almost 55%. In the US, we exported more than 8 billion with a 15% growth rate, and to the UK, we achieved a 21% growth rate. This demonstrates the robust growth of the Indian pharmaceutical industry, even in challenging situations. As long as India continues to manufacture quality drugs at affordable prices, the industry
will remain unmatched.”
Emphasizing on the potential of pharma trade between India and Turkey, The Consul General, Consulate General of Turkey, Mr. Orhan Yalman Okan, said “Hyderabad is becoming a global city, particularly in the pharma sector, making it the pharma capital of India. Both India and Turkey are rising in this field, presenting significant trade and cooperation opportunities In 2022, the global pharmaceutical market reached a value of USD 1.5 trillion, with Turkey ranking 21st. The Turkish pharmaceutical market grew by an impressive 80%, reaching around USD 38 billion and unit sales hitting USD 2.8 billion. The industry employs over 45,000 staff and offers over 12,000 products. Turkey's pharmaceutical exports were USD 2.2 billion, reaching over 170 countries. The medical devices market was USD 2.9 billion, and medical tourism contributed USD 2.5 billion. PharmaLytica 2024 aims to foster deeper understanding and cooperation within the pharmaceutical domain. By sharing pertinent insights into Turkey's pharmaceutical landscape, including its remarkable growth trajectory, regulatory framework, and export prowess, we aim to cultivate a clearer understanding of the sector's potential.”
Shri. AVPS Chakravarthi, Ambassador, World Packaging Organisation & Board Member Pharmexcil, said, "Pharmalytica has grown into a permanent landmark of innovation in the pharmaceutical industry from Mumbai to Bangalore and now Hyderabad.In lifesaving and lifesustaining industries, there's no room for compromise on quality. Our exports to highly regulated markets like the USA, where over 50% of our products are consumed, reflect our uncompromising standards. The collaboration between India and US authorities aims to ensure the availability of safe, highquality drugs. Hyderabad, often referred to as the second Silicon Valley of the world, integrates digital and chemical technologies, making it a hub for pharmaceutical innovation. The city hosts more than 214 USFDAapproved facilities, accounting for over 35% of
India’s pharmaceutical production. Additionally, Hyderabad is a significant center for medical devices and packaging, having become selfsufficient even during the COVID19 supply chain challenges.”
Speaking on the sidelines of inaugural, Dr. Gaurav Pratap Singh, Senior Principal Scientific Officer, Indian Pharmacopoeia Commission said, “India's reputation as the 'Pharmacy of the World' is wellearned, with our commitment to supplying highquality and affordable medicines globally. Our leadership in vaccine supply to WHO, coupled with meeting the generics demands of the USA, Britain, and Europe, underscores our pivotal role in healthcare accessibility. The significant growth in biosimilars approvals and manufacturing further enhances patient access to biopharmaceuticals. With strategic investments in developing generic and biopharmaceutical versions, India stands poised to maintain its global pharmaceutical leadership. Innovation remains paramount, especially in emerging prophylactic and therapeutic products like medical devices, complex generics, monoclonal antibodies, and gene therapy. Setting robust regulations for their development and marketing is crucial for sustained growth. While quality concerns highlighted by WHO and other regulatory agencies necessitate stringent quality control measures, platforms like PharmaLytica 2024 play a vital role in prioritizing quality in the pharmaceutical sector. Looking ahead, there's immense potential to replicate the success of hubs like Hyderabad and Bengaluru in Tamil Nadu and Kerala, creating new avenues for growth in the pharma industry."
Addressing the opportunities in this sector, Mr. Yogesh Mudras, Managing Director, Informa Markets in India said, “In 2024, the Indian pharmaceutical industry remains a global leader across the entire supply chain. It ranks third in production by volume and in terms of Active Pharmaceutical Ingredients ( APIs ) globally. With over 500 different APIs manufactured domestically, India contributes 57% of APIs to the WHO's prequalified list. The medical devices
sector in India stands at a market size of US$ 11 billion. By 2032, the India analytical laboratory instruments market is projected to hit $4142.85 million, propelled by the government's focus on boosting production, notably supported by the flourishing pharmaceutical sector.
Situated in Hyderabad, the epicentre of India's bulk drug production, and nestled within South India's mature pharma ecosystem, Pharmalytica emerges as a vital regional hub for industry leaders and stakeholders with discussions surrounding emerging trends, prevalent challenges, and promising opportunities.”
Mr.Deepak Khurana, Vice PresidentProcurement & SCM, Suven Pharmaceuticals Limited said, The Indian pharmaceutical industry is experiencing significant growth and promising prospects. India leads in generic drug manufacturing and exports, meeting global demand for affordable medications. The emphasis on biopharmaceuticals and biosimilars is increasing, driven by their rising demand. The COVID19 pandemic has accelerated digital health solutions and telemedicine adoption, transforming healthcare delivery. Regulatory reforms are set to boost innovation and quality. Indian pharmaceutical companies are ramping up R&D investments for novel drug discoveries. Expansion into emerging markets and a focus on specialty pharmaceuticals further fuel growth. Despite challenges like pricing pressures and regulatory complexities, the industry is poised for continued advancement.”
Offering the industry perspective, Dr. Subhash Thuluva, Sr. Vice President & Head Clinical Development, Biological E. Limited said “With Indian Pharmaceutical exports projected to grow by 10%, India remains a key global supplier, earning the title 'Pharmacy of the World’ solidified, catering to 20% of the global demand for generics. The government's Production Linked Incentive ( PLI ) schemes are driving domestic manufacturing, aiming to reduce dependency on imports and enhance competitiveness. Additionally, increased healthcare spending, rising from 1.4% of GDP in 2019 to 2.1% in 2023, supports infrastructure development, particularly in rural areas. As India's pharmaceutical landscape evolves, strategic investments in R&D are imperative. Beyond incremental advances, there's a pressing need for innovation across disease spaces, leveraging India's talent pool and mature ecosystems like Hyderabad. Amidst changing global market dynamics, adherence to quality standards, regulatory compliance,
(Continued on page ......8)
(Continued from page ......6)
of highquality APIs. Owing to such factors, the captive manufacturing type is expected to witness significant adoption, which will drive the development of the segment and thereby expand the growth of the market during the forecast period.
Significant Market Trends
A paradigm shift in the manufacturing process is one of the primary market trends. Traditionally, India has been known for producing generic drugs, but there is a significant movement toward complicated and highvalue API manufacture. This transition is being driven by causes such as rising global demand for specialty pharmaceuticals, the necessity for complicated new therapeutics, and severe regulatory regulations. Further, the emphasis on R&D promotes innovation in API synthesis methods, process optimization, and green chemistry practices. Furthermore, the synthesis of complicated chiral APIs and peptides is gaining traction, reflecting the industry's search for higher value products. Additionally, the paradigm change demonstrates the industry's resilience and dedication to remaining ahead of global pharmaceutical manufacturing trends. Therefore, the paradigm shift from captive manufacturing to contract manufacturing is anticipated to have a positive impact on the market during the forecast period.
Major Challenges
A stringent regulatory environment is a significant challenge that affects market expansion. The lowcost structure in India has led to a more rapid and expansive boost in manufacturing in India. Regulatory scrutiny of manufacturers, particularly in Asia, remains very high; however, quality problems continue to persist, mainly due to the intensive manufacturing in the region. Globally, this county represents a significantly growing, organized, highly regulated market for pharmaceutical products, owing to the presence of a proper regulatory framework
(Continued from page ......1)
this event is tailored to provide valuable insights and foster meaningful connections. A panel discussion is a dynamic and engaging way to explore complex topics, foster debate, and share knowledge among experts and audiences alike.
Panel Discussion!
In today's fastpaced world, staying ahead of the curve is crucial. Our panel discussion offers a unique opportunity for delegates to delve deep into the most pressing issues and emerging opportunities within the [industry/topic]. Whether you're a seasoned professional, an aspiring entrepreneur, or a curious enthusiast, this event is tailored to provide valuable insights and foster meaningful connections. A panel discussion is a dynamic and engaging way to explore complex topics, foster debate, and share knowledge among experts and audiences alike.
First day will have panel discussion on Regulatory development of Sustainable Quality Culture in pharma, role of regulatory framework, automation & workforce, medical devices.
Second day will have panel discussion on Preclinical and Clinical Research
1) Translational Research: Bridging
guiding the development, approval, manufacturing, and commercialization of pharmaceutical products. Moreover, with the growth of a large and expanding generic drug industry, along with the global expansion of the chemical and pharmaceutical industries, the production of bulk actives has increased significantly in India. International sourcing of APIs started to exhibit a growing concern for the pharmaceutical industry. Nonadherence to these guidelines might restrict the entry of APIs into the regulated markets, thereby causing significant losses to API manufacturers. This discourages manufacturers from venturing into the API industry, thereby limiting the development prospects of the market during the forecast period.
Conclusion
In 2022, India's pharmaceutical business underwent a tremendous transformation, moving from being a volume producer to a valued supplier. PostCOVID19, the Indian pharma sector has gained momentum as a key player in the global markets. India sets to double its API market in the next 3 years, says Saurabh Mukherjee, Founder and Chief Investment Officer of Marcellus Investment Managers. Cuttingedge research and development in the production of generic APIs would only be possible with the proper regulatory support—through PLI schemes and other incentives—combined with trained, highskilled individuals. With the ongoing efforts, India is wellpositioned to become a global leader in the pharmaceutical industry.
(Continued from page ......7) and strategic R&D investments are essential for maintaining competitiveness.” Dr. SD Sinha, Senior Vice President Development, Hetero Group of Companies, said “The evolution of India's pharmaceutical sector is a testament to its resilience and adaptability. From generics API and formulations to a diverse array of products including differentiated generics, biologicals, medical devices, and blood products, India's pharmaceutical landscape has undergone significant transformation. Vertical integration and a focus on uniform quality standards underscore the industry's commitment to excellence.
This year’s edition saw participation of over 8,000 visitors and more than 200 exhibitors showcasing 1000+ brands. They reaffirmed the need and focus of PharmaLytica as an industry event to boost and facilitate the pharmaceutical sector.
(The author is assistant professor, department of pharmaceutical sciences, Bengal College of Pharmaceutical Sciences & Research and he can bereached at ashiquesumel007@gmail.com)
the Gap between Preclinical and Clinical Studies
2 ) Emerging Technologies in Preclinical and Clinical Research
3 ) Patient Centric Approaches in Preclinical and Clinical Research
4 ) Regulatory Compliance Good Laboratory Practice (GLP) and Good Clinical Practice (GCP)
Third day will have panel discussion on Biosimilars and Peptide
1 ) Analytical Characterization ofBiosimilars
2) Analytical Techniques for peptide Analysis
3) Biosimilars Characterization
a) UP SCALE
b) DOWN SCALE
4th July will also have knowledge session on NABL Accreditation and its benefits. The points that will be discussed are
1
) Explain the importance and relevance of NABL accreditation.
2) Outline the process of obtaining NABL accreditation and the criteria involved.
3
) Highlight the benefits and advantages of being NABL accredited, such as improved quality assurance, increased customer confidence, and international recognition.
4) Address any queries regarding the accreditation process and its
implementation within an institution.
Why in Gujarat?
Over the past two decades, Gujarat has become one of the most preferred locations for industrial investment in India. Gujarat has achieved an annual growth rate of over 10% p.a. over the past five years and is one of the most industrialized states of India. It accounts for 16% of the nation’s industrial production and 22% of its exports. Gujarat possesses several advantages which have enabled it to chart a path of rapid growth and industrialization such as sound infrastructure facilities, availability of skilled and semiskilled manpower, excellent domestic and international connectivity and rich natural resources. The key differentiating factor has been Gujarat’s investorfriendly policy towards industrial development. These have resulted in Gujarat evolving as the hub of India’s chemical and petrochemical industry – with the state accounting for more than half of India’s total chemical industry and ~63% of total national petrochemical production. The chemical industry is today the largest and fastest growing component of Gujarat’s manufacturing sector.
Gujarat leads India in Pharmaceutical, Petrochemicals, CRO, Chemical Industry & Agriculture and
Key exhibitors includeHetero, Emvee Engineers, Schneider Electric, Integrated Cleanroom Technology, Nicomac Taikisha Clean Rooms, HLE Glascoat Ltd, Scientific Research Instruments Company, Ami Polymer and many more. The expos are primarily supported by industry associations such as BDMAI (Bulk Drug Manufacturers Association ( India ) , FOPE ( Federation of Pharma Entrepreneurs ) and IPC ( Indian Pharmacopoeia Commission ) Additionally, Telangana Life Sciences serves as a supporting partner, while ETRIC is the emobility partner for the event.
enjoys the share between 35% 44% of the national share over last two decade. Ahmedabad, Baroda, Surat, Dahej, Rajkot, Mehsana, Vapi, Valsad, Ankleshwar, Bharuch are a few gems in this very prosperous state of Gujrat that stand out & create an aura of opportunity. An exhibition encompassing all these along with the neighbouring states is bound to have more reach and is surely going to create a mark in the exhibition industry.
• Gujarat Accounting for nearly 42% share of India’s pharmaceutical turnover
• Gujarat’s pharmaceutical industry has evolved into an innovationdriven, Knowledge focused industry.
• In, recent years Gujarat develop into an ideal location for global clinical research
• Pharmaceutical development It is an established manufacturing base for bulk drugs and formulations – With its inherent competitive advantages – is poised to capture emerging global Opportunities to become a global pharmaceuticals hub. The emergence of SEZs is likely to create a pharma behemoth with scale and infrastructure on par with International standards, that will enable it to compete in the global marketplace.
NDC DRUG & CHEMICAL CO.PVT.LTD.
EMAILID: hdshah2050@gmail.com
LIST OF PRODUCTS
l 2‐Bromo‐2‐Nitro‐1‐3‐Propanediol 99%
l Aceclofenac Ip
l Acesulfame Potassium Bp/Usp/Ep
l Acrypol (Carbomer)–934,940 & All Grades
l Acrypol 956 (Sani琀zer Grade)
l Acrypol Elt20
l Acrycoat L‐100/S‐100
l Acrysol K‐140/K‐150
l Azithromycin Ip
l Kyron T‐314/T‐114/T‐134
l Adrenaline Bitartrate Ip
l Alpha Lipoic Acid
l Ambroxol Hcl Ip
l Ammonium Sulphate
l Benfo琀amine
l Benzocaine Ip.
l Benzoic Acid Ip ‐ Ganesh
l Bronopol Ip/Bp (Niranjan/Surya)
l Cholecalciferol Ip
l Chlorpheniramine Maleate Bp
l Citric Acid Mono Ip – Sunil / Vasa
l Clotrimazole
l Copper Sulphate Pentahydrate
l Cyanocobalamine Ip
l Dapagliflozin Propanediol Monohydrate
l Deflazacort Ihs
l Dexamethasone Sodium Phosphate Ip
l Dextromethorphan Hydrobromide Ip
l Disodium Hydrogen Citrate Bp
l Dl Methionine Feed Grade
l Doxycycline Hyclate Ip
l Edta Disodium
l Edta Tetra Sodium
l Ferric Ammonium Citrate Ip
l Gamabenzene Hexachloride
l Guaifenesin Ip
l Hydrocor琀sone Acetate Ip/Ep
l Ivermec琀n Ip
l L‐Glutamic Acid Bp
l L‐Lysine Hcl Usp (Devendra Kir琀/Suprim
l Light Magnesium Carbonate Ip
l Loperamide Hcl Ip
l M.A.G.
l Magnesium Sulphate 7h2o
l Malic Acid
l Manganese Sulphate
l Methyl Cobalamine Ip
l Methyl Prednisoline Ep/Ip/Usp
l Neotame (Fcc/Usp)
l Niacinamide Ip
l Orthophenylphenol
l Ornidazole Bp
l Oxetacaine Bp
l Phenylephrine Hcl Ip
l Potassium Citrate Ip
l Potassium Iodide Ip
l Potassium Sorbate
l Povidone Iodine Ip
l Pvpk 30
l Pyridoxine Hydrochloride Ip
l Sodium Acetate Trihydrate
l Sodium Benzoate Bp‐China
l Sodium Benzoate Ip‐Ganesh
l Sodium Chloride Ip
l Sodium Citrate – Cambodia /Vasa/Sunil
l Sodium Gluconate
l Sodium Hydroxide Pellets
l Sodium Metabisulphite
l Sodium Sacharine Bp
l Sodium Selenite
l Sorbic Acid
l Sucralfate Usp (China)
l Sucralose Fcc/Usp/Nf
l Tannic Acid
l Thiamine Hydrochloride Ip
l Tolna昀ate Usp
l Triclosan
l Tricholine Citrate 65% Soln
l Vegarol 1618ta(Ceto Stearyl Alcohol
l Vitamin A Palmitate 1.7 Miu/G
l Vitamin C Coated
l Vitmamin C Plain (Ascorbic Acid)
l Vitamin D3 Stabilised 850ip Water Soluble
l Vitamin E Acetate Liquid
l Vitamin E Dry Powder 50% Pharma
l Xanthan Gum – Meihua (China)
l Xanthan Gum – Fufeng (China)
l Xanthan Gum (Transparent Grade)Austria
l Zinc Sulphate Heptahydrate
l Zinc Sulphate Monohydrate
PRODUCT LIST
Name of productPharmacopeiaTherapeu琀c useName of productPharmacopeiaTherapeu琀c use
API (HUMAN) COMMERCIAL
CITICOLINE SODIUMIP / USPNOOTROPIC
CITICOLINE BASEUSPNOOTROPIC
BUPROPION HYDROCHLORIDEUSPANTIDEPRESSANT
GRANISETRON HYDROCHLORIDEIP / BP / USPLOCAL ANAESTHETIC
MELOXICAMIP / BP / USP / EPANTI-INFLAMMATORY
PIROXICAMIP / BP / USP / EPANTI-INFLAMMATORY
PRILOCAINEIP / BP / EP / USPLOCAL ANAESTHETIC
PRILOCAINE HYDROCHLORIDEBP / EP / USPLOCAL ANAESTHETIC
LIDOCAINE HYDROCHLORIDE MONOHYDRATE IP / BP / USP / EPLOCAL ANAESTHETIC
LIDOCAINEIP / BP / USP / EP5-HT3 RECEPTOR ANTAGONISTS
ALBENDAZOLEIP / BP / USPANTHELMINTIC
ARTICAINE HYDROCHORIDEIP / BP / EPLOCAL ANAESTHETIC UNDER DEVELOPMENT
Mob: +91 8689897373 l Email: enquiry@cheminopharma.com Web: www.cheminopharma.com
MOBILE NUMBER: PRITESH GOHIL: 9324265877 / 9324540033, RUPESH GOHIL: 9324517446 l Email Id: Info@hapenterprise.com
Office: Shop No. 4, Disha Chs Ltd., L. T. Road, Gorai-ii, Plot No. 50, Opp. Shanti Dham Ashram, Next To Maxus Mall, Borivali (west). Mumbai-400092 . ACTIVE PHARMACEUTICAL INGREDIENTS
v ACECLOFENAC
v ALLOPURINOL
v AMITRIPTYLINE
v AMLODIPINE BESILATE
v ARIPIPRAZOLE
v ARTEMETHER
v ATROVASTATIN CALCIUM
v BACLOFEN
v BENFOTIAMINE
v BENZOCAINE
v BETAHISTINE DI HCL
v BROMHEXINE HCL
v CALCITROL
v CALCIUM DOBESILATE
v CARBAMAZEPINE
v CARVEDILOL
v CELECOXIB
v CETIRIZINE DI HCL
v CHLORPHENIRAMINE MALEATE
v CHONDROITIN SODIUM
v CILNIDIPINE
v CINNARIZINE
v CITICOLINE SODIUM
v CLOBETASOL PROPIONATE
v CLOMIPHENE CITRATE
v CLOMIPRAMINE HCL
v CLOPIDOGREL BISULPHATE
v CLOTRIMAZOLE
v CLOZAPINE
v CYCLOBENZAPRINE HCL
v CYPROHEPTADINE
v DAPOXETINE HCL
v D-BIOTIN
v DEFLAZACORT
v DESLORATADINE
v DESVENLAFAXINE SUCCINATE
v DEXAMETHASONE PLAIN / SODIUM
v DEXTROMETHORPHAN HYDROBOMIDE
v DIACEREIN
v DICLOFENAC DIETHYLAMINE
v DICLOFENAC POTASSIUM
v DICLOFENAC SODIUM
v DICYCLOMINE HCL
v DOTHIEPIN HCL
v DOXEPIN HCL
v DOXYLAMINE SUCCINATE
v DULOXETINE HCL
v DUTASTERIDE
v EBASTIN
v EPERISONE HCL
v ESCITALOPRAM OXALATE
v ETHAMSYLATE
v ETODOLAC
v ETORICOXIB
v FEBANTEL
v FEBUXOSTAT
v FENOFIBRATE /MICRONISED
MUPIROCIN
v FEXOFENADINE
v FLUCONAZOLE
v FLUNARIZINE
v FLUPENTIXOL HCL
v FOLIC ACID
v FUROSEMIDE
v FUSIDIC ACID
v GABAPENTIN
v GLICLAZIDE
v GLIMEPIRIDE
v HYDROXYZINE HCL
v IMIPRAMINE HCL
v INDOMETACIN
v ISOTRETINOIN
v ITOPRIDE
v IVERMECTIN
v KETOPROFEN
v LABETALOL
PRODUCT LIST
l Croscarmellose Sodium IP / BP / USP / EP
v LACOSAMIDE
v LAMOTRIGINE
v LEFLUNOMIDE
v LEVO SALBUTAMOL SULPHATE
v LEVOCETIRIZINE HYDROCHLORIDE
v LEVOSULPRIDE
v LINAGLIPTIN
v LINEZOLID
v LOPERAMIDE
v LORATADINE
v LORNOXICAM
v LOSARTAN POTASSIUM
v LULICONAZOLE
v LUMEFANTRINE
v MEBEVERINE HCL
v MECLIZINE
v MEDOXOMIL
v MEFENAMIC ACID
v MELATONIN
v MELITRACEN HCL
v MELOXICAM
v MESALAMINE
v METADOXINE
v METFORMIN HCL
v METHYLCOBALAMINE
v METHYLPREDNISOLONE
v METOCLOPRAMIDE
v METOPROLOL SUCCINATE / TARTRATE
v MINOXIDIL
v MIRTAZAPINE
v MONTELUKAST SODIUM
v MOXIFLOXACIN
v NIACINAMIDE
v NIFEDIPINE
v NIMESULIDE
v NORTRIPTYLINE HCL
v OLANZAPINE
v OLMESARTAN
v ONDANSETRON
v PANTOPRAZOLE SODIUM
v PAROXETINE HCL
v PHENYLEPHRINE HYDROCHLORIDE
v PIOGLITAZONE HCL
v PIROXICAM v PREGABALIN
v PROGESTERONE
v PYRANTEL PAMOATE
v QUETIAPINE FUMRATE
v RACECADOTRIL v RIBOFLAVIN SODIUM PHOSPHATE
v ROSUVASTATIN CALCIUM
v S - AMLODIPINE v SERTACONAZOLE NITRATE
v SILDENAFIL CITRATE v SMX / TMP v SODIUM FUSIDATE
v SULFASALAZINE
v SULPHADIAZINE v TACROLIMUS v TADALAFIL v TAMSULOSIN HCL v TELMISARTAN v TENELIGLIPTIN v TICAGRELOR v TOLPERISONE v TOPIRAMATE v TORSEMIDE v TRANEXAMIC ACID v TRIFLUOPERAZINE HCL
v TRIHEXYPHENIDYL HCL
v TRIMETAZIDINE v VENLAFAXINE HCL v VILDAGLIPITIN v VITAMIN C PLAIN & COATED v VITAMIN E 50%
l Sodium Carboxymethyl cellulose IP / BP / USP / EP
l Calcium CMC IP/ BP / USP / EP
l Sodium Starch Glycolate (Potato Based / Corn Base)
l Sodium Alginate IP / BP/ USP / EP
l Guar Gum IP / BP / USP / EP
l Guar Acacia IP / BP / USP / EP
l Gum Xanthan IP / BP / USP / EP
l Alginic Acid IP/ BP/ USP
We are pleased to introduce ourselves as one of the manufacturers in India since 1978. We have grown to a world class company catering to mul琀na琀onals worldwide under the leadership of our MD, Mr. Amit Shah (Specialized in Hydrocolloid Chemistry).
We have a dedicated R & D team headed by a highly experienced team consis琀ng of post graduates in Pharmaceu琀cal Chemistry and we constantly strive to cater to client’s needs. We firmly believe that SALE IS NOT AN END OF A RELATIONSHIP, BUT JUST A BEGINNING OF OUR SERVICES...
Regd Office : GALA NO.121, RAJA INDUSTRIAL ESTATE, P.K.ROAD, MULUND (WEST), MUMBAI ‐ 400 080. TEL: +91 22 61540303/04/05 l Mobile No : +91 9769761752, 8879212125 Email Id : saleshydro@amitgroup.in
ORGANIC IODINE DERIVATIVES
l Ethyl Iodide
l Methyl Iodide
l Periodic Acid 50% and 99%
l Potassium Metaperiodate
l Sodium Metaperiodate
l Trimethyl Silyl Iodide
l Trimethyl Sulphoxonium Iodide
INORGANIC IODINE DERIVATIVES
l Calcium Iodate – Monohydrate
l Calcium Iodate – Anhydrous
l Copper Iodide
l Ethylenediamine Dihydroiodide (EDDI)
l Hydroiodic Acid 57%
l Iodine Monochloride
l Potassium Iodate
l Potassium Iodide
l Potassium Iodide – Stabilized
l Sodium Iodate
l Sodium Iodide
ACTIVE PHARMA INGREDIENTS (API)
l Diliodohydroxyquinoline (Iodoquinol)
l Iodochlorohydroxyquinoline (Clioquinol)
l Iodoform
l Oxyquinoline Sulphate
l Potassium Hydroxyquinoline Silphate
l Povidone Iodine
l Povidone Iodine 20%
l Thymol Iodide
l Bromine Compounds
l Calcium Bromide
l Potassium Bromide
l Sodium Bromide
CONTRAST MEDIA
l Barium Sulphate
l Microbar
SELENIUM COMPOUNDS
l Selenium Sulphide
CALCIUM REPLENISHMENT
l Calcium Levulinate
NEW PRODUCTS
l 2‐Chloro 5‐Iodo Benzoic Acid (CIBA)
l 4‐Iodoaniline
l 3,5‐Diiodo Salicylic Acid
l 5‐Iodo 2‐Methyl Benzoic Acid (MIBA)
l Diiodomethane
l Iodobenzene
l L‐Selenomethionine
l N‐Bromosuccinimide
l N‐Iodosuccinimide
l (R)
Methylhexanoic Acid (RCMH)
l Selenious Acid
Mumbai Office Address: 3 – A, Shiv Sagar Estate North Wing, Dr. Annie Besant Road, Worli, Mumbai 400 018, India
Corp. Office: Ground Floor, Usha Building, S. V. Road, Near Nanavati Hospital, Vile Parle (West), Mumbai-400056, Maharashtra.
Tel: +91(022) 26104647 / 25188195
Mobile: +91(0) 9768456789 / 9768312345
Email: info@siddhambikaimpex.com
Fresenius Kabi Austria is one of the leading lactulose suppliers, with more than 40 years of experience in its production and distribution. We supply lactulose in liquid and crystalline form manufactured at two production sites in Linz, Austria, and in Vicchio, Italy.
For more information on our Lactulose product portfolio and services, please contact our Indian Distributor.
ALLURA RED LAKE AMARANTH LAKE BRILLIANT BLUE FCF LAKE
CARMOISINE LAKE CHOCOLATE BROWN HT LAKE ERYTHROSINE LAKE
FAST GREEN FCF LAKE FAST RED E LAKE INDIGO CARMINE LAKE
PONCEAU 4R LAKE QUINOLINE YELLOW LAKE
TARTRAZINE LAKE SUNSET YELLOW FCF LAKE
BLENDED LAKES APPLE / PEA GREEN / BLACK / BROWN LAKE
IRON OXIDE (RED / YELLOW / BLACK / BROWN )
Also available D & C Colours and D & C Lakes Like Green 5, 6 / Violet 1,2 / Yellow 7,8 / Red 4,6,7,17,19,21,22,27,28,30.33,36. Available Pearl Pigments in various shades
Green House, 2nd Floor, Green Street, Fort, Mumbai 400 023.
Phone: 022‐22662136 / 22663119 l Mobile: 9820026621
Email: sales@siddhint.com l Web: www.siddhint.com
MFG: ANIMAL, CATTLE, AQUA & POULTRY
FEED SUPPLEMENTS / ADDITIVES
MANUFACTURING SPECIALITY
l Choline Chloride 60%Cereal Base
l Choline Chloride 60%Corn Base
l Choline Chloride 50%Silica Base
l Choline Chloride 50%Corn Base
l Choline Chloride 75%Liquid
l Choline Chloride 70%Liquid
l Choline Chloride 60%Liquid
l Choline Chloride 97‐98%Pure
l Di‐Calcium Phosphate (Dcp)
l Tri‐Calcium Phosphate (Tcp)
l Monocalium Phosphate (Mcp)
l Toxin Binder (Datox)
l Phytase 5000昀u/Granular/Powder
l Cocktail Enzymes l Mono Sodium Phosphate
l Vitamin Premix
MANUFACTURING
SPECIALITY
l Choline Chloride75/90/60 Liquid For Oil Driling
MINERALS
l Hydrated Lime
l Precipitataed Silica
l Bentonite Powder
l Quick Lime
l Dolomite Powder
l Dextrose Monohydrate
l Salt (Sodium Chloride)
l Table Salt l Industrial Salt
l Iodised Salt
l Copper Sulphate
l Zinc Sulphate l Zinc Oxide
l Ferrous Sulphate (Crysal/Powder)
l Cobalt Sulphate
l Dry Jawla Fish
l Bhel Kuta Mix Dry Fish
l Sun Dry Fish
AGRO PRODUCTS
l Rice Ddgs l Rice Bran
l Rice Bran Oil
l De Oil Rice Bran
l Soyabeen Oil l Rice Gluten
l Chickpeas l Groundnut Meal
l Soyabeen Meal
l Co琀onseed Meal
l Rapeseed Meal
l Cocopit Powder l Cereal Maize
l Maize Bran Powder
l Wheat Bran Powder
l Rice Flour l Corn Flour
l Corn (Yelloow Maize)
l Soybean Meal
l Soya Protein Powder
l Soya Protein Isolate
l Broken Rice l Wheat Grains
AMINO ACIDS
l Dl‐Methionine F.G.99%
l L‐Lysine (Hcl)
l L‐Theronine F.G.98.5%
l L‐Tryptophan 98.5%
l Chlortetracycline 15%
l Tylosin Phosphate 10%
l Tiamulin Funerate 10%
VITAMINS
l Vitamin‐A 1,00,000i.U l
l
l
l
OTHER PRODUCTS
l Acidifier l Formic Acid l Bronopol
l Humic Acid l Mono Sodium Glutante
l Magnesium Sulphate l Manganese Sulphate
l Sodium Bi Carbonate l Sodium Humate
l Sodium Perborate l Sodium Percarbonate
l Calcium Propionate l Calcium Carbonate
l Calcium Sulphate l Calcium Chloride
l Di Amonium Phosphate
l Potassium Nitrate l Potassium Chloride
ENZYMES
l Phytase 5000 Granules l Xylanase
l Alkaline Protease l Beta Glucanase
l Cellulase l Lipase l Neutral Protease
l Pec琀nase l Cocktail Enzyme
l Enzymes With Probio琀cs FISH MEAL POWDER
l Steam Sterilized Fish Meal
l Sun Dry Fish Meal
l Aquaculture Fish Meal l 60+
FLAVOURS & AROMA CHEMICALS AND OILS l HERBAL POWDERS CONTRACT MANUFACTURING CAN BE DONE IF REQUIRED
Contact Us: 101 Neelkanth Apartment, F.p No. 284, Opp. Ram Mandir Extn. Road, Opp. Janki Mata Mandir, Vazira Naka, Borivali West, Mumbai, M aharashtra - 400091, India Mob: Harish S. Anandpara: 91-9820048309 | Sagar H. Anandpara: 91-9930160151 Email: harishanandpara@yahoo.in / sagaranandpara007@gmail.com / info@sdaproducts.com | Web: www.sdaproducts.in, www.indiamart.com/sdaproducts
AUTHORISED STOCKISTS : METALAB / SHANTI SCI.
• THOMAS BAKER CHEMICALS
Dealers / Stockists : SDFCL•
We Stock & Supply :
Chemicals and Bio- Chemicals for Research and Industry Manufactured by Merck (Germany), BDH (UK), Sigma (USA), Aldrich (USA), Difco & Oxoid Culture Media , Lancaster (UK), ICN (USA).
Chemicals : Glaxo , E-merck, BDH, SRL -SD's , Ranbaxy, Loba - Chemie Spectrochem, Hi - Media.
Sartorius (German) / Pall (UK) / Millipore Membrane Filter Papers, Prefilteres and Filtration Assemblies, Filter Pads, all sizes with or without hole as per required sized, Filter Cartridges.
Whatman Filter Papers, Thimbles, Chromatography Sheets and Glass Microfibre Filters for Enviornment and Pollution Control Testing. Laboratory Sealing & Parafilm.
TLC/ HPTLC / Gas Chromatography Equipments and Spares, GC/ HPLC Grade Chemicals, Phases, Supports, Columns etc. Top/Hamilton (USA), SGE, Micro Syrings Reference Standards.
Pharmaceutical Raw Materials, Solvents ( Bulk & Small Packing).
Precoated TLC, Plates Merck
(Germany) for TLC/HPTLC. Certified Reference Material (Standards). Ethanol for UV & HPLC /AR 99.95% China /Hayman (UK) & Merck (Germany) Borosil / Riviera Glasswares, Glass Assemblies upto 200 Ltr. Hydrometers, Hygrometers
Dealers & Re-packers of Laboratory Chemicals. We Provide Laboratory chemicals in BULK & Small Packing. We Organize your EXPORT Order for Laboratory Chemicals.
